CTLA4 and neoplasm: Immune checkpoint inhibitors block the interaction between checkpoint proteins and their ligands (e.g., PD-1/PD-L1, CTLA-4/B7), restoring T-cell activity and enabling the immune system to recognise and attack tumour cells [20,21].